What is the 13F Pro Quality Score for DERM?

13F Pro ranks Journey Medical Corp (DERM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DERM's current score at https://13fpro.ai/research/DERM (free sign-up required for the full ranking).

Where does 13F Pro source DERM data?

All Journey Medical Corp fundamentals and ownership data come directly from SEC EDGAR. Journey Medical Corp files with the SEC under CIK 1867066. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DERM in?

Journey Medical Corp (DERM) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DERM research updated on 13F Pro?

DERM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Journey Medical Corp(DERM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1867066 DERM stock profile & AI dashboard →

13F Pro Quality Score

26.4/100

Rank #2,510 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

44.0/100

Profitability

15.0/100

Balance Sheet

14.8/100

Earnings Quality

30.0/100

Free Cash Flow

23.3/100

Institutional Flow

92.4/100

Revenue Scale

12.9/100

Dilution Risk

16.8/100

DERM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Journey Medical Corp (DERM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DERM at 26.4/100 on a 32-signal composite quality model, placing it at rank #2,510 of 2,879 stocks — the bottom half of the AI-ranked universe. DERM scores in the top quartile across institutional flow (92.4). Areas of concern include revenue scale (12.9) and balance sheet strength (14.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Journey Medical Corp reports quarterly revenue of $16.0M, net income of $-2.2M, an operating margin of -9.3%. Top institutional holders of DERM by reported 13-F value include WASATCH ADVISORS, TANG CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. DERM trades on the Nasdaq exchange and files with the SEC under CIK 1867066. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DERM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Journey Medical Corp directly from SEC EDGAR. Journey Medical Corp's 13F Pro composite quality score has ranged between 17 and 34 since 2024, currently 26.4 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.

Revenue

Q1 2026

$16.0M

Net Income

Q1 2026

$-2.2M

Free Cash Flow

Q1 2026

$2.9M

Operating Margin

Q1 2026

-9.3%

D/E Ratio

Q1 2026

0.90

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.2% YoY

$61.9MFY 2025

FY22 $73.7MFY23 $79.2MFY24 $56.1MFY25 $61.9M

Net Income

+22.1% YoY

$-11.4MFY 2025

FY22 $-29.6MFY23 $-3.9MFY24 $-14.7MFY25 $-11.4M

Operating Income

+40.3% YoY

$-8.2MFY 2025

FY22 $-27.5MFY23 $-2.1MFY24 $-13.7MFY25 $-8.2M

EPS (Diluted)

+34.7% YoY

$-0.47FY 2025

FY22 $-1.69FY23 $-0.21FY24 $-0.72FY25 $-0.47

Total Assets

+17.9% YoY

$94.6MFY 2025

FY22 $105.2MFY23 $76.8MFY24 $80.2MFY25 $94.6M

Total Debt

+1.6% YoY

$25.3MFY 2025

FY22 $27.8MFY23 $14.6MFY24 $24.9MFY25 $25.3M

Op. Cash Flow

-36.3% YoY

$-12.4MFY 2025

FY22 $-13.5MFY23 $5.2MFY24 $-9.1MFY25 $-12.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$61.9M +10.2%	$56.1M -29.1%	$79.2M +7.5%	$73.7M +16.7%	$63.1M +41.8%	$44.5M
Net Income	$-11.4M +22.1%	$-14.7M -280.8%	$-3.9M +87.0%	$-29.6M +32.7%	$-44.0M -932.7%	$5.3M
Operating Income	$-8.2M +40.3%	$-13.7M -559.8%	$-2.1M +92.5%	$-27.5M +21.1%	$-34.9M -544.3%	$7.9M
EPS (Diluted)	$-0.47 +34.7%	$-0.72 -242.9%	$-0.21 +87.6%	$-1.69 +60.9%	$-4.32 -981.6%	$0.49
Total Assets	$94.6M +17.9%	$80.2M +4.4%	$76.8M -26.9%	$105.2M +8.1%	$97.3M +87.4%	$51.9M
Total Debt	$25.3M +1.6%	$24.9M +70.1%	$14.6M -47.3%	$27.8M	—	—
Operating Cash Flow	$-12.4M -36.3%	$-9.1M -274.2%	$5.2M +138.7%	$-13.5M -520.5%	$-2.2M -142.5%	$5.1M

AI Insight: DERM Financial Trends

Revenue stabilizing near $16M but persistent operating losses and rising debt undermine financial health.

• Revenue recovered to $16M in Q1 2026 after dipping to $13M in Q1 2025, but remains below Q3 2025 peak of $18M.

• Operating losses narrowed to $-1M in Q1 2026 from $-3M in Q1 2025, showing marginal operational improvement.

• Total debt rose 40% from $20M in Q2 2024 to $28M in Q1 2026 while equity remains volatile and insufficient.

⚠ Operating cash flow swung sharply negative to $-6M in Q4 2025, then recovered to $3M in Q1 2026—volatility signals execution risk.

⚠ Debt-to-equity ratio deteriorated to 0.9x in Q1 2026 from 1.8x in Q2 2024, indicating increasing financial leverage.

AI Insight: DERM Ratio Trends

Journey Medical swung to profitability in Q4 2025 but slipped back into losses in Q1 2026, signaling operational volatility rather than sustainable recovery.

• Operating margin improved from -19.7% in Q2 2024 to -2.8% in Q4 2025, but reversed to -9.3% in Q1 2026.

• Leverage fell sharply: D/E ratio dropped from 1.81 in Q3 2024 to 0.79 in Q4 2025, improving balance sheet strength.

• ROIC remains deeply negative across all periods shown; TTM ROIC of -10.8% indicates persistent value destruction.

⚠ Q4 2025 profitability appears anomalous; Q1 2026 reversion to -9.3% OpMargin and -28.9% ROE suggests seasonal or one-time benefit.

⚠ D/E rising back to 0.90 in Q1 2026 after Q4 2025 improvement; trend reversal warrants monitoring.

Get alerted when DERM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Journey Medical Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DERM

WASATCH ADVISORS LP
$10.0M2,133,370 sh
TANG CAPITAL MANAGEMENT LLC
$7.6M1,610,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.1M1,082,080 sh
BlackRock, Inc.
$4.6M972,862 sh
Opaleye Management Inc.
$4.5M960,000 sh
J. Goldman & Co LP
$2.3M500,188 sh
Pale Fire Capital SE
$2.3M481,987 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.2M463,202 sh
UBS Group AG
$1.8M390,138 sh
MILLENNIUM MANAGEMENT LLC
$1.8M383,067 sh

Fund	Value	Shares
WASATCH ADVISORS LP	$10.0M	2,133,370
TANG CAPITAL MANAGEMENT LLC	$7.6M	1,610,000
VANGUARD CAPITAL MANAGEMENT LLC	$5.1M	1,082,080
BlackRock, Inc.	$4.6M	972,862
Opaleye Management Inc.	$4.5M	960,000
J. Goldman & Co LP	$2.3M	500,188
Pale Fire Capital SE	$2.3M	481,987
GEODE CAPITAL MANAGEMENT, LLC	$2.2M	463,202
UBS Group AG	$1.8M	390,138
MILLENNIUM MANAGEMENT LLC	$1.8M	383,067

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DERM on your watchlist

Track score changes the day Journey Medical Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DERM a good stock to buy?

13F Pro's AI-powered analysis of Journey Medical Corp (DERM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DERM are available on the DERM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DERM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DERM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Journey Medical Corp's investment landscape.